Table 2
The schedule of enrolment, interventions and assessments of this trial
| Time point | Study period | |||||
| Enrolment | Allocation | Postallocation | Close-out | |||
| March 2023 | 2023 | Day 0 | Day 14 | Day 28 | End-2023 | |
| Enrolment: | ||||||
| Eligibility screen | X | |||||
| Informed consent | X | |||||
| Allocation | X | |||||
| Interventions: | ||||||
| (IPL+DQS) |  | |||||
| (DQS) |  | |||||
| (IPL) | X | X | ||||
| Assessments: | ||||||
| (The baseline variables) | X | X | ||||
| (The primary outcome) | X | X | X | |||
| (The second outcome) | X | X | X | |||
DQS, diquafosol; IPL, intense pulsed light.